The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Survival of patients with neuroblastoma before versus after reduction of therapy due to the change in age cut-off from 12 to 18 months in Children’s Oncology Group (COG) risk stratification.
 
Wendy B. London
Consulting or Advisory Role - Jubilant Radiopharma; Merck
Research Funding - Agios; Aileron Therapeutics; Bluebird Bio; Bristol-Myers Squibb; Novartis
 
Hannah Bender
No Relationships to Disclose
 
Meredith Irwin
Honoraria - Bayer
 
Michael D. Hogarty
No Relationships to Disclose
 
Robert P. Castleberry
No Relationships to Disclose
 
John M. Maris
Stock and Other Ownership Interests - Tantigen Bio
Consulting or Advisory Role - Auron Therapeutics; Illumina Radiopharmaceuticals; Jubilant DraxImage
Patents, Royalties, Other Intellectual Property - GPC2 binders and CARs (Inst); Neuroblastoma antigens (Inst)
 
Pei-Chi Kao
No Relationships to Disclose
 
Arlene Naranjo
Consulting or Advisory Role - Novartis
 
Susan Lerner Cohn
Stock and Other Ownership Interests - Abbvie; Accelerated Medical Diagnostics; Amgen; Amgen; Amgen (I); AstraZeneca/MedImmune; Gilead Sciences; Johnson & Johnson/Janssen; Lilly; Merck; Novartis; Novo Nordisk; Pfizer; Pfizer (I); Sanofi; Teva; Teva; United Health Group
Honoraria - Y-mAbs Therapeutics
Research Funding - Merck (Inst); United Therapeutics (Inst)